Milestone Alert: First Subject Dosed in Phase 2b Vitiligo Trial of Novel BET Inhibitor
The Dermatology Digest
JUNE 5, 2024
Check out TDD’s one-on-one interview with Iain Stuart, PhD , Chief Scientific Officer at Vyne Therapeutics. The randomized, double-blind, vehicle-controlled trial will evaluate the safety and efficacy of once-daily VYN201 topical gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks.
Let's personalize your content